A new strategy to combat a highly aggressive form of brain tumor has shown promise in initial experiments involving a small number of patients. Researchers have developed a novel approach where patients' own immune cells are transformed into 'living drugs' capable of identifying and attacking glioblastoma, a type of brain cancer known for its rapid growth and resistance to treatment.
The innovative CAR-T therapy, commonly used for blood-related cancers like leukemia, has been adapted by separate teams at Massachusetts General Hospital and the University of Pennsylvania to target solid tumors such as glioblastoma. These next-generation CAR-T versions are designed to overcome the tumor's defenses and enhance the immune system's ability to locate and destroy cancer cells.
